A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01313637
First received: March 10, 2011
Last updated: February 20, 2014
Last verified: February 2014
  Purpose

This is a phase III multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder, GW642444 Inhalation Powder and Placebo when administered once-daily via a Novel Dry Powder Inhaler over a 24-week treatment period in subjects with COPD. Subjects who meet eligibility criteria at Screening (Visit 1) will complete a 7 to14 day run-in period followed by a randomization visit (Visit 2) then a 24-week treatment period. There will be a total of 9 clinic study visits. A follow-up phone contact for adverse event assessment will be conducted approximately one week after the last study visit (Visit 9 or Early Withdrawal). The total duration of subject participation in the study will be approximately 27 weeks. A subset of subjects at selected sites will also perform 24-hour serial spirometry and Holter monitoring during the study and provide serial blood samples for pharmacokinetic analysis. Sparse pharmacokinetic sampling for population pharmacokinetic analyses will be obtained from non-subset subjects. The primary measure of efficacy is clinic visit trough (pre-bronchodilator and pre-dose) FEV1 on Treatment Day 169. Safety will be assessed by adverse events, 12-lead ECGs, vital signs, clinical laboratory tests, and 24 hour Holter monitoring (subset only).


Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: GSK573719/GW642444 125/25mcg
Drug: GSK573719 125mcg
Drug: GW642444 25mcg
Drug: Placebo only
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) [ Time Frame: Baseline and Day 169 ] [ Designated as safety issue: No ]
    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 28, 56, 84, 112, 168, and 169. Baseline is defined as the mean of the assessments made 30 minutes pre-dose and 5 minutes pre-dose on Treatment Day 1. Trough FEV1 is defined as the mean of the FEV1 values obtained at 23 and 24 hours after the previous morning's dosing (ie., trough FEV1 on Day 169 is the mean of the FEV1 values obtained 23 and 24 hours after the morning dosing on Day 168). Change from Baseline at a particular visit was calculated as the trough FEV1 at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline , smoking status, center group, day, and day by Baseline and day by treatment interactions. ITT=Intent-to-Treat; par.=participants.


Secondary Outcome Measures:
  • Mean Transition Dyspnea Index (TDI) Focal Score at Day 168 (Week 24) [ Time Frame: Day 168 (Week 24) ] [ Designated as safety issue: No ]
    Considered an 'other' endpoint by the FDA. The TDI is an interviewer-administered instrument which measures the changes in the participant's dyspnea from Baseline. This questionnaire was collected on Days 28, 84 and 168. The scores in the TDI evaluate ratings for 3 different categories (functional impairment, magnitude of task in exertional capacity, and magnitude of effort). TDI scores ranged from -3 (major deterioration) to +3 (major improvement); total score = -9 to 9. Analysis was performed using a repeated measures model with covariates of treatment, Baseline dyspnea index (BDI) focal score,smoking status, center group, day, day by BDI focal score and day by treatment interactions.

  • Change From Baseline in Weighted Mean (WM) 0-6 Hour FEV1 Obtained Post-dose at Day 168 [ Time Frame: Baseline and Day 168 ] [ Designated as safety issue: No ]
    FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. The WM FEV1 was derived by calculating the area under the FEV1/time curve (AUC) using the trapezoidal rule, and then dividing the value by the time interval over which the AUC was calculated. The WM was calculated at Days 1, 28, 84, and 168 using the 0-6-hour post-dose FEV1 measurements collected on that day, which included pre-dose (Day 1: 30 minutes [min] and 5 min prior to dosing; other serial visits: 23 and 24 hours after the previous morning dose) and post-dose at 15 min, 30 min, 1 hour, 3 hours, and 6 hours. Change from Baseline at a particular visit was calculated as the WM at that visit minus Baseline. Analysis was performed using a repeated measures model with covariates of treatment, Baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, center group, day, and day by Baseline and day by treatment interactions.


Other Outcome Measures:
  • Change From Baseline in the Mean Shortness of Breath With Daily Activities (SOBDA) Score for Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    The newly developed SOBDA questionnaire assesses dyspnea or shortness of breath (SOB) with daily activities. The SOBDA questionnaire is made up of 13 items completed by the participant (par.) each evening prior to bedtime, when the par. is instructed to reflect on the current day's activities. The daily score is computed as the mean of the scores on the 13 items (>=7 items must have non-missing responses for this to be calculated). The par. is assigned a weekly mean SOBDA score ranging from 1 to 4 (greater scores indicate more severe breathlessness with daily activities) based on the mean of 7 days of data (>=4 of 7 days must be completed for a weekly mean to be calculated). Change from BL is the mean weekly SOBDA score minus BL. Analysis was performed using MMRM with covariates of treatment, BL (mean score in the week prior to treatment), smoking status, center group, week, week by BL and week by treatment interactions. This MMRM analysis only included Weeks 4, 8, 12, and 24.


Enrollment: 1493
Study Start Date: March 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GSK573719/GW642444
125/25mcg
Drug: GSK573719/GW642444 125/25mcg
125/25mcg
Other Name: umeclidinium bromide/vilanterol trifenatate
Experimental: GSK573719
125mcg
Drug: GSK573719 125mcg
125mcg
Other Name: umeclidinium bromide
Experimental: GW642444
25mcg
Drug: GW642444 25mcg
25mcg
Other Name: vilanterol trifenatate
Placebo Comparator: Placebo
Placebo
Drug: Placebo only
Placebo
Other Name: placebo

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of COPD
  • 10 pack-year or greater history of cigarette smoking
  • Post-bronchodilator FEV1/FVC of <0.7
  • Predicted FEV1 of 70% of normal or less
  • Modified Medical Research Council (mMRC) dyspnea score of 2 or greater

Exclusion Criteria:

  • Women who are pregnant, lactating, or planning to become pregnant
  • Respiratory disorders other than COPD, including a current diagnosis of asthma
  • Clinically significant non-respiratory diseases or abnormalities that are not adequately controlled
  • Significant allergy or hypersensitivity to anticholinergics, beta2-agonists, or the excipients of magnesium stereate or lactose used in the inhaler delivery device
  • Hospitalization for COPD or pneumonia within 12 weeks prior to screening
  • Lung volume reduction surgery within 12 weeks prior to screening
  • Abnormal and clinically significant ECG findings at screening
  • Clinically significant laboratory findings at screening
  • Use of systemic corticosteroids, antibiotics for respiratory tract infections, strong cytochrome P450 3A4 inhibitors, high dose inhaled steroids (>1000mcg fluticasone propionate or equivalent), PDE4 inhibitors, tiotropium, oral beta2-agoinists, short- and long-acting inhaled beta2-agonists, ipratropium, inhaled sodium cromoglycate or nedocromil sodium, or investigational medicines for defined time periods prior to the screening visit
  • Use of long-term oxygen therapy (12 hours or greater per day)
  • Regular use of nebulized treatment with short-acting bronchodilators
  • Participation in the acute phase of a pulmonary rehabilitation program
  • A know or suspected history of alcohol or drug abuse
  • Affiliation with the investigational site
  • Previous use of GSK573719 or GW642444 alone or in combination, including the combination of fluticasone furoate and GW642444
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01313637

  Hide Study Locations
Locations
United States, Alabama
GSK Investigational Site
Jasper, Alabama, United States, 35501
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85006
United States, California
GSK Investigational Site
Long Beach, California, United States, 90822
GSK Investigational Site
Los Angeles, California, United States, 90095
GSK Investigational Site
Palo Alto, California, United States, 94304
GSK Investigational Site
Riverside, California, United States, 92506
GSK Investigational Site
San Diego, California, United States, 92117
GSK Investigational Site
San Diego, California, United States, 92103-8415
GSK Investigational Site
Torrance, California, United States, 90502
United States, Florida
GSK Investigational Site
Clearwater, Florida, United States, 33765
GSK Investigational Site
DeLand, Florida, United States, 32720
GSK Investigational Site
Orlando, Florida, United States, 32822
GSK Investigational Site
Panama City, Florida, United States, 32405
United States, Kansas
GSK Investigational Site
Topeka, Kansas, United States, 66606
United States, Michigan
GSK Investigational Site
Livonia, Michigan, United States, 48152
United States, Minnesota
GSK Investigational Site
Plymouth, Minnesota, United States, 55441
United States, Nebraska
GSK Investigational Site
Lincoln, Nebraska, United States, 68506
United States, New Jersey
GSK Investigational Site
Cherry Hill, New Jersey, United States, 08003
United States, North Carolina
GSK Investigational Site
Charlotte, North Carolina, United States, 28207
United States, South Carolina
GSK Investigational Site
Easley, South Carolina, United States, 29640
GSK Investigational Site
Greenville, South Carolina, United States, 29615
GSK Investigational Site
Spartanburg, South Carolina, United States, 29303
GSK Investigational Site
Union, South Carolina, United States, 29379
United States, Virginia
GSK Investigational Site
Richmond, Virginia, United States, 23225
Belgium
GSK Investigational Site
Aalst, Belgium, 9300
GSK Investigational Site
Edegem, Belgium, 2650
GSK Investigational Site
Genk, Belgium, 3600
GSK Investigational Site
Kortrijk, Belgium, 8500
GSK Investigational Site
Liège, Belgium, 4000
Denmark
GSK Investigational Site
Aalborg, Denmark, 9100
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
København, Denmark, 2400
GSK Investigational Site
Naestved, Denmark, 4700
GSK Investigational Site
Odense C, Denmark, 5000
GSK Investigational Site
Roedovre, Denmark, 2610
GSK Investigational Site
Roskilde, Denmark, 4000
Estonia
GSK Investigational Site
Haapsalu, Estonia, 90502
GSK Investigational Site
Parnu, Estonia, 80010
GSK Investigational Site
Rakvere, Estonia, 44316
GSK Investigational Site
Tallinn, Estonia, 10138
GSK Investigational Site
Tallinn, Estonia, 10117
GSK Investigational Site
Tartu, Estonia, 51014
France
GSK Investigational Site
Lyon cedex 04, France, 69317
GSK Investigational Site
Montauban cedex, France, 82017
GSK Investigational Site
Nice, France, 06000
GSK Investigational Site
Perpignan, France, 66000
GSK Investigational Site
Reims Cedex, France, 51092
GSK Investigational Site
Tarbes Cedex 09, France, 65013
GSK Investigational Site
Toulon, France, 83000
GSK Investigational Site
Toulouse cedex 9, France, 31059
GSK Investigational Site
Tours cedex 9, France, 37044
GSK Investigational Site
Vieux Condé, France, 59690
Germany
GSK Investigational Site
Dillingen, Bayern, Germany, 89407
GSK Investigational Site
Kuenzing, Bayern, Germany, 94550
GSK Investigational Site
Muenchen, Bayern, Germany, 80809
GSK Investigational Site
Schwabach, Bayern, Germany, 91126
GSK Investigational Site
Frankfurt, Hessen, Germany, 60596
GSK Investigational Site
Gelnhausen, Hessen, Germany, 63571
GSK Investigational Site
Neu-Isenburg, Hessen, Germany, 63263
GSK Investigational Site
Rodgau, Hessen, Germany, 63110
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 51069
GSK Investigational Site
Magdeburg, Sachsen-Anhalt, Germany, 39112
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Leipzg, Sachsen, Germany, 04109
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Geesthacht, Schleswig-Holstein, Germany, 21502
GSK Investigational Site
Schmoelln, Thueringen, Germany, 04626
GSK Investigational Site
Berlin, Germany, 14059
GSK Investigational Site
Berlin, Germany, 13581
GSK Investigational Site
Berlin, Germany, 10117
GSK Investigational Site
Berlin, Germany, 10787
GSK Investigational Site
Berlin, Germany, 13125
GSK Investigational Site
Berlin, Germany, 10367
GSK Investigational Site
Hamburg, Germany, 20246
GSK Investigational Site
Hamburg, Germany, 22143
GSK Investigational Site
Hamburg, Germany, 20253
Hungary
GSK Investigational Site
Balassagyarmat, Hungary, 2660
GSK Investigational Site
Budapest, Hungary, 1529
GSK Investigational Site
Debrecen, Hungary, 4032
GSK Investigational Site
Deszk, Hungary, 6772
GSK Investigational Site
Farkasgyepű, Hungary, 8582
GSK Investigational Site
Gyöngyös, Hungary, 3200
GSK Investigational Site
Gödöllő, Hungary, 2100
GSK Investigational Site
Nyíregyháza, Hungary, 4400
GSK Investigational Site
Szikszó, Hungary, 3800
GSK Investigational Site
Szombathely, Hungary, 9700
GSK Investigational Site
Sátoraljaújhely, Hungary, 3980
GSK Investigational Site
Törökbálint, Hungary, 2045
Japan
GSK Investigational Site
Aichi, Japan, 454-8502
GSK Investigational Site
Aichi, Japan, 457-8510
GSK Investigational Site
Aichi, Japan, 455-8530
GSK Investigational Site
Chiba, Japan, 296-8602
GSK Investigational Site
Fukuoka, Japan, 802-0052
GSK Investigational Site
Fukuoka, Japan, 814-0180
GSK Investigational Site
Fukuoka, Japan, 811-3195
GSK Investigational Site
Fukuoka, Japan, 832-0059
GSK Investigational Site
Hokkaido, Japan, 070-8644
GSK Investigational Site
Ibaraki, Japan, 319-1113
GSK Investigational Site
Kanagawa, Japan, 252-0001
GSK Investigational Site
Miyagi, Japan, 989-1253
GSK Investigational Site
Okayama, Japan, 714-0081
GSK Investigational Site
Osaka, Japan, 596-8501
GSK Investigational Site
Shizuoka, Japan, 434-8511
GSK Investigational Site
Tokyo, Japan, 171-0014
GSK Investigational Site
Tokyo, Japan, 194-0023
GSK Investigational Site
Tokyo, Japan, 204-8585
Netherlands
GSK Investigational Site
Alkmaar, Netherlands, 1815 JD
GSK Investigational Site
Almelo, Netherlands, 7609 PP
GSK Investigational Site
Almere, Netherlands, 1311 RL
GSK Investigational Site
Beek, Netherlands, 6191 JW
GSK Investigational Site
EDE, Netherlands, 6716 RP
GSK Investigational Site
Eindhoven, Netherlands, 5623 EJ
GSK Investigational Site
Enschede, Netherlands, 7513 ER
GSK Investigational Site
Groningen, Netherlands, 9728 NP
GSK Investigational Site
Helmond, Netherlands, 5707 HA
GSK Investigational Site
Hoorn, Netherlands, 1624 NP
GSK Investigational Site
Tubbergen, Netherlands, 7651 JH
GSK Investigational Site
Veldhoven, Netherlands, 5504 DB
GSK Investigational Site
Zutphen, Netherlands, 7207 AE
Norway
GSK Investigational Site
Bekkestua, Norway, N-1357
GSK Investigational Site
Bergen, Norway, 5017
GSK Investigational Site
Bodø, Norway, 8005
GSK Investigational Site
Elverum, Norway, 2408
GSK Investigational Site
Kløfta, Norway, 2040
GSK Investigational Site
Skedsmokorset, Norway, N-2020
GSK Investigational Site
Stavanger, Norway, 4005
GSK Investigational Site
Trondheim, Norway, 7011
GSK Investigational Site
Trondheim, Norway, 7027
Philippines
GSK Investigational Site
Cebu City, Philippines, 6000
GSK Investigational Site
Dasmariñas, Cavite, Philippines, 4114
GSK Investigational Site
Marikina City, Philippines, 1800
GSK Investigational Site
Marilao, Bulacan, Philippines, 3019
GSK Investigational Site
Quezon City, Philippines, 1109
Slovakia
GSK Investigational Site
Bardejov, Slovakia, 085 01
GSK Investigational Site
Humenne, Slovakia, 066 01
GSK Investigational Site
Poprad, Slovakia, 058 01
GSK Investigational Site
Revuca, Slovakia, 050 01
GSK Investigational Site
Spisska Nova Ves, Slovakia, 052 01
GSK Investigational Site
Vrable, Slovakia, 952 01
Sweden
GSK Investigational Site
Göteborg, Sweden, SE-412 63
GSK Investigational Site
Göteborg, Sweden, SE-413 45
GSK Investigational Site
Höllviken, Sweden, SE-236 32
GSK Investigational Site
Linköping, Sweden, SE-582 16
GSK Investigational Site
Luleå, Sweden, SE-971 89
GSK Investigational Site
Lund, Sweden, SE-221 85
GSK Investigational Site
Malmö, Sweden, SE-211 52
GSK Investigational Site
Stockholm, Sweden, SE-111 57
GSK Investigational Site
Stockholm, Sweden, SE-113 61
GSK Investigational Site
Vällingby, Sweden, SE-162 68
Ukraine
GSK Investigational Site
Donetsk, Ukraine, 83099
GSK Investigational Site
Ivano-Frankivsk, Ukraine, 76018
GSK Investigational Site
Kharkiv, Ukraine, 61037
GSK Investigational Site
Kharkiv, Ukraine, 61124
GSK Investigational Site
Kiev, Ukraine, 03680
GSK Investigational Site
Kyiv, Ukraine, 03680
GSK Investigational Site
Simferopol, Ukraine, 95043
GSK Investigational Site
Zaporizhia, Ukraine, 69035
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01313637     History of Changes
Other Study ID Numbers: 113361, 2010-023348-33
Study First Received: March 10, 2011
Results First Received: December 19, 2013
Last Updated: February 20, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
anticholinergic
long-acting beta agonist

Additional relevant MeSH terms:
Chronic Disease
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Disease Attributes
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 01, 2014